Liftstream is an executive search recruitment company in the life sciences sector
New Enterprise Associates backs veteran rare diseases executive team
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Boston Biotech, Cristina Csimma, Cydan Corporation, FDA, Jon Saxe, KLS Partners, LUM-001, Lumos Pharma, NEA, New England Associates, Orphan drugs, Prosensa, Rare Disease, Rick Hawkins, Sante Ventures, unmet medical needs
Leave a comment
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Avalon Ventures, BLiNK, CDC Enterprise, DMD, Duchenne Muscular Dystrophy, European Research Institutes, France, GSK, Idinvest Partners, KLS Partners, Kurma, Kurma Biofund, Kurma Life Science Partners, NEA, New Enterprise Associates, oncology, Orphan drugs, partnering, Prosensa, rare diseases, VC, venture capital
Leave a comment
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AstraZeneca, Cambridge MA, Clarus Ventures, Cydan, David Mott, DMD, Dr. Cristina Csimma, Duchenne Muscular Dystrophy, GSK, International Rare Diseases Research Consortium, James McArthur, MedImmune, NEA, Orphan Drug, orphan drug accelerator, Prosensa, Rare Disease, Treat-NMD, Virdante Pharmaceuticals, Wyeth
Leave a comment
It’s as simple as ADC for Mersana Therapeutics
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, American Association for Cancer Researc, Antibody-drug conjugates, David Mott, Endo Pharmaceuticals, Fidelity Biosciences, Immunogen, Mersana Therapeutics, NEA, New Enterprise Associates, Pfizer Venture Fund, PureTech Ventures, Roche, seattle genetics, Timothy B. Lowinger, Washington
Leave a comment